Home >> Life Sciences >> Pharmaceuticals >> General Pharmaceuticals

Chronic Obstructive Pulmonary Disease - Heat Map and Analysis

Published: Jun-2016 | Format: PDF | GBI Research | Number of pages: 15 | Code: MRS - 96481


Chronic Obstructive Pulmonary Disease (COPD) is a progressive disorder associated with chronic inflammation of the airways and lungs. Persistent breathing difficulties and repeated exacerbations of COPD symptoms make the disease one of the leading causes of morbidity, and the fifth-leading cause of death in the world.

The disease is characterized by structural changes that result in a narrowing of the small airways, ultimately causing airflow limitation. Both parenchymal destruction ? termed emphysema ? and small airways disease ? referred to as chronic bronchitis ? contribute towards these changes, which occur in varying degrees in each patient.

Bronchodilators are established as the main classes of pharmacological maintenance treatment in COPD. They can be administered orally, intravenously or, if preferred, inhaled. The various forms of bronchodilators can be classed as short-acting or long-acting, and both are used in the management of COPD. Although bronchodilators play the key role in the management of COPD symptoms, other forms of treatment are also widely used. Inhaled corticosteroids (ICS) such as fluticasone propionate and budesonide are used to manage inflammation in both COPD and asthma patients. ICSs bind to the glucocorticoid receptors in the airways, reducing inflammation. In addition, there are signs of more innovative products emerging onto the treatment landscape. An example includes a monoclonal antibody ? a class of therapy that has already emerged for asthma ? that is in Phase III development.

The differences between many of these products are relatively nuanced, and must be understood fully by companies seeking to position a novel drug in this market. This tabular heatmap framework, designed to provide an easily digestible summary of these clinical characteristics, provides detailed information on all late-stage clinical trial results for products in the COPD market and late-stage pipeline. These are split along lines of therapy, and are therefore reflective of the treatment algorithm.

All safety and efficacy endpoints reported in these trials are displayed, for both the drug and comparison groups. In addition, key study characteristics such as the size, composition and patient segment of the study population are provided. These results are presented in a visually accessible, color-coded manner in order to maximize ease of use.

The accompanying text provides a detailed analysis of the clinical benchmarks set by the current market landscape, and the anticipated changes to these benchmarks, and to the treatment algorithm, as a result of the late-stage pipeline.

Scope

  • What are the clinical characteristics of currently approved therapies for COPD, in terms of specific safety and efficacy parameters?
  • What are the key unmet needs in this indication, and which clinical safety and efficacy parameters are most closely linked to them?
  • Which novel classes of combination therapy are expected to emerge in the treatment of COPD?
  • Which first-in-class products are in development for COPD and what targets do they act upon?
  • Which sub-types of patients could potentially benefit from these new products?

Reasons to buy

  • Understand the current clinical landscape by considering the treatment options available for each patient segment.
  • Visually compare the currently approved treatments available at each line of therapy, based on the most important efficacy and safety parameters tested in clinical trials.
  • Assess the current late-stage pipeline, in terms of the likely positioning of each product and the implications for the clinical landscape at each line of therapy.
  • Understand the relative strengths and weaknesses of the studies used to gather these data.
  • Build up a nuanced understanding of the clinical benchmarks set by these products, and consider how the current late-stage pipeline will affect these benchmarks.
  • Assess your own pipeline programs in light of these benchmarks in order to optimally position them and maximize uptake by clinicians.


Table of Contents

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 2

2 Introduction 3
2.1 Report Guidance 4

3 Marketed Products 5
3.1 Mild COPD 5
3.2 Moderate-to-Severe COPD 5
3.3 Very Severe COPD 7

4 Pipeline Products 9
4.1 Changes to Mild COPD, 2016-2022 9
4.2 Changes to Moderate-to-Severe COPD, 2016-2022 9
4.3 Changes to Very Severe COPD, 2016-2022 11

5 Appendix 12
5.1 Abbreviations 12
5.2 References 13
5.3 Research Methodology 15
5.4 Contact Us 15
5.5 Disclaimer 15   


List of Tables

Table 1: COPD Market, Disease Severity, 2016 3
Table 1: COPD Market, Disease Severity, 2016 3

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields


Related Reports

North America Pharmaceutical Market by Manufacturers, Countries, Type and Application, Forecast to 2022

Sep-2017 | Global Info Research | Pages : 119 | Code : MRS-166762 | 4480

The pharmaceutical industry discovers, develops, produces, and markets drugs or pharmaceutical drugs for use as medications. Pharmaceutical companies may deal in generic or brand medications. Scope of the Report: This report focuses on the Pharmaceutical in North America market, especially in United States, Canada and Mexico. This report categorizes the market based on manufacturers, countries, type and application. Market Segment by Manufacturers, this report covers Novartis Read more

North America Pinaverium Bromide Market by Manufacturers, Countries, Type and Application, Forecast to 2022

Sep-2017 | Global Info Research | Pages : 116 | Code : MRS-166761 | 4480

Pinaverium Bromide is a medicine available in a number of countries worldwide. Pinaverium Bromide is a drug used for functional gastrointestinal disorders. It belongs to a drug group call antispasmodic and acts as a calcium channel blocker in helping to restore the normal contraction process of the bowel. It is most effective when taken for a full course of treatment and is not designed for immediate symptom relief or sporadic, intermittent use. Scope of the Report: This report focuse Read more

North America Ophthalmology Amniotic Membrane Market by Manufacturers, Countries, Type and Application, Forecast to 2022

Sep-2017 | Global Info Research | Pages : 116 | Code : MRS-166760 | 4480

Amniotic membrane (AM) can function in the eye as a basement membrane substitute or as a temporary graft. It has anti-inflammatory and anti-scarring effects and contains growth factors that promote epithelial wound healing on the surface of the eye. Scope of the Report: This report focuses on the Ophthalmology Amniotic Membrane in North America market, especially in United States, Canada and Mexico. This report categorizes the market based on manufacturers, countries, type and applica Read more

Asia-Pacific Docusate Sodium Market by Manufacturers, Regions, Type and Application, Forecast to 2022

Sep-2017 | Global Info Research | Pages : 120 | Code : MRS-166617 | 4480

Docusate sodium is a versatile and highly effective and efficient pharmaceutical grade surfactant. Docusate sodium is often used as an exicipient in pharmaceutical production processes where it acts as a solubilizing agent for poorly soluble API's as well as a dispersing and emulsifying agent. It is also used as active pharmaceutical ingredients (API) in the production of stool softeners and prenatal and geriatric iron preparations. Scope of the Report: This report focuses on the Docusa Read more

United States Neurofeedback System Market by Manufacturers, States, Type and Application, Forecast to 2022

Sep-2017 | Global Info Research | Pages : 115 | Code : MRS-166485 | 4480

Neurofeedback is a non-invasive method of direct brain function training. It is also a type of biofeedback and is therefore, also called EEG Biofeedback. It uses the electrodes (which act like tiny microphones) placed on the client's scalp to record and amplify the EEG, or brainwaves and control auditory, visual, and/or tactile feedback which allows learning to take place. This operant learning initiates self-regulation and enhances relaxation, both necessary components of good brain functi Read more

Global (North America, Europe and Asia-Pacific, South America, Middle East and Africa) Sphygmomanometers Market 2017 Forecast to 2022

Sep-2017 | Global Info Research | Pages : 118 | Code : MRS-166484 | 4880

This report studies the Sphygmomanometers market. Sphygmomanometer, also called blood pressure meter, blood pressure monitor, or blood pressure gauge, is an instrument for measuring arterial blood pressure. Scope of the Report: This report focuses on the Sphygmomanometers in Global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application. Market Segmen Read more

Hepatitis C Therapeutics in Asia-Pacific Markets to 2023 - Presence of Outstanding Direct-Acting Antivirals and Late-Stage Pipeline to Transform the Clinical and Commercial Landscape

Aug-2017 | GBI Research | Pages : 0 | Code : MRS-166015 | 4995

Hepatitis C is a blood-borne liver disease caused by the hepatitis C virus (HCV), which can lead to acute and chronic hepatitis infection. According to the World Health Organization (WHO), in 2015 there were 1.75 million new HCV infections globally, and approximately 399,000 people die each year from hepatitis C, mostly due to cirrhosis and hepatocellular carcinoma. The APAC region has diverse HCV epidemiology, with prevalence ranging from 0.1% to 4.7%, and a unique genotype (GT) distributi Read more

Global Smoking Cessation Products Market Research Report 2017

Sep-2017 | QY Research | Pages : 102 | Code : MRS-165986 | 2900

In this report, the global Smoking Cessation Products market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Smoking Cessation Products in these regions, from 2012 to 2022 (forecast), covering - North America - Europe - China - Japan - Southeast Read more

Global Salicylamide Market Research Report 2017

Sep-2017 | QY Research | Pages : 106 | Code : MRS-165978 | 2900

In this report, the global Salicylamide market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Salicylamide in these regions, from 2012 to 2022 (forecast), covering - North America - Europe - China - Japan - Southeast Asia - India Global Salicyl Read more

Global Colloids (Blood Plasma) Market Research Report 2017

Sep-2017 | QY Research | Pages : 111 | Code : MRS-165972 | 2900

In this report, the global Colloids (Blood Plasma) market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Colloids (Blood Plasma) in these regions, from 2012 to 2022 (forecast), covering - North America - Europe - China - Japan - Southeast Asia - Read more

Single User | $(USD)2000 View Pricing